{
  "treatment_regimens": [
    "chemotherapy",
    "immunotherapy",
    "Atezolizumab",
    "Avelumab",
    "Durvalumab",
    "Ipilimumab",
    "Nivolumab",
    "Pembrolizumab",
    "Tremelimumab",
    "chemotherapy-ICI combination"
  ],
  "countries": [
    "France"
  ],
  "populations": [
    {
      "stage, histology": "IV, non-squamous lung cancer",
      "pdl1_status": "\u226550%",
      "n": 133
    },
    {
      "stage, histology": "IV, non-squamous lung cancer",
      "pdl1_status": "<50% or negative",
      "n": 1019
    },
    {
      "stage, histology": "IV, squamous lung cancer",
      "pdl1_status": "\u226550%",
      "n": 4
    },
    {
      "stage, histology": "IV, squamous lung cancer",
      "pdl1_status": "<50% or negative",
      "n": 24
    },
    {
      "stage, histology": "IV, unknown",
      "pdl1_status": "unknown",
      "n": 3856
    }
  ],
  "results": {
    "chemotherapy": {
      "median_os": "11.6 months",
      "one_year_survival": "48.9%",
      "median_rw_pfs": "4.0 months"
    },
    "immunotherapy": {
      "median_os": "16.4 months",
      "one_year_survival": "60.8%",
      "median_rw_pfs": "5.0 months"
    },
    "group_difference": "Improved OS was observed for the immunotherapy group after 3 months (HR = 0.59; 95%CI [0.42\u20130.83], p < 0.01)"
  },
  "study_name": "Study from Belaroussi 2023.pdf",
  "file_name": "Belaroussi 2023.pdf"
}